Skip to content
Clinical Trials – home

Nebivolol Hydrochloride: A Comprehensive Guide for Patients

0 / 2
trials open to patients / all trials
2+
Countries

In short

Nebivolol Hydrochloride, a third-generation beta-blocker, is being studied in various clinical trials for its potential benefits in treating cardiovascular conditions. These trials aim to evaluate its effectiveness in managing hypertension, improving heart function, and addressing specific cardiovascular issues like microvascular angina and coronary artery spasms. The unique properties of Nebivolol, including its ability to increase nitric oxide production and its antioxidant effects, make it a promising candidate for improving cardiovascular health in diverse patient populations.

At a glance

Drug Name
Nebivolol Hydrochloride
Drug Class
Third-generation beta-blocker
Main Conditions Studied
Hypertension, Heart Failure, Microvascular Angina, Coronary Artery Spasms, Cardiac Steatosis
Unique Properties
Nitric oxide production stimulation, Antioxidant effects
Dosage Forms
Oral tablets (various strengths)
Common Dosages in Trials
5-10 mg daily
Key Outcome Measures
Blood pressure changes, Exercise capacity, Heart function parameters, Quality of life
Special Population Focus
Elderly patients, Women with microvascular angina
Comparative Studies
vs. Carvedilol, vs. Diltiazem, vs. Monotherapies

What is Nebivolol?

Nebivolol, also known by the brand name Bystolic, is a medication that belongs to a class of drugs called beta-blockers. It's specifically classified as a third-generation, selective beta-1 blocker. This means it primarily affects certain receptors in the heart and blood vessels, making it useful for treating various cardiovascular conditions.

Uses of Nebivolol

Nebivolol is primarily used to treat the following conditions:

  • Hypertension (High Blood Pressure): This is the most common use of nebivolol. It helps lower blood pressure by reducing heart rate and relaxing blood vessels.
  • Heart Failure: Some studies have investigated the use of nebivolol in elderly patients with heart failure, particularly those with preserved ejection fraction (a measure of how well the heart pumps blood).
  • Coronary Artery Spasm: Research is being conducted to determine if nebivolol can help patients with coronary artery spasm, a condition where the arteries supplying the heart temporarily narrow.
  • Microvascular Angina: This is a type of chest pain caused by problems with the small blood vessels of the heart. Some studies are exploring nebivolol's potential in treating this condition.

How Nebivolol Works

Nebivolol works in several ways to improve heart health and lower blood pressure:

  1. Beta-1 Receptor Blocking: It selectively blocks beta-1 receptors in the heart, which slows down heart rate and reduces the force of heart contractions.
  2. Nitric Oxide Production: Unlike many other beta-blockers, nebivolol also stimulates the production of nitric oxide in blood vessels. Nitric oxide is a natural substance that helps blood vessels relax and widen, improving blood flow.
  3. Antioxidant Effects: Nebivolol has antioxidant properties, which means it can help protect blood vessels from damage caused by harmful molecules called free radicals.

These unique properties make nebivolol different from older beta-blockers and potentially more beneficial for certain patients.

Dosage and Administration

The dosage of nebivolol can vary depending on the condition being treated and the individual patient. However, based on the clinical trials reviewed:

  • For hypertension, a common starting dose is 5 mg once daily, which may be increased to 10 mg daily if needed.
  • For heart failure studies, doses ranged from 2.5 mg to 10 mg daily.
  • Nebivolol is typically taken orally (by mouth) in the morning, with or without food.

It's crucial to follow your doctor's instructions regarding dosage and not to adjust your dose without consulting your healthcare provider.

Potential Side Effects

While nebivolol is generally well-tolerated, like all medications, it can cause side effects. Common side effects may include:

  • Headache
  • Fatigue
  • Dizziness
  • Slow heart rate (bradycardia)

If you experience any severe side effects or allergic reactions, seek medical attention immediately.

Ongoing Research

Several clinical trials are currently exploring new potential uses for nebivolol:

  • Cardiac Steatosis: Researchers are investigating whether nebivolol can help reduce the buildup of fat in heart cells, a condition known as cardiac steatosis.
  • Exercise Tolerance: Studies are examining if nebivolol can improve exercise capacity in patients with heart conditions.
  • Comparison with Other Beta-Blockers: Some trials are comparing nebivolol to other beta-blockers like carvedilol to determine if it offers any advantages in treating heart failure.

These ongoing studies may provide more information about the potential benefits and uses of nebivolol in the future.

Questions people often ask

Conditions where Nebivolol Hydrochloride is being studied

Each condition opens its own overview and trial list

Trials with Nebivolol Hydrochloride

Recruiting trials first

See all 2 →
Quick filters
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).